Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market Today

Company Performance - Vertex Pharmaceuticals is set to disclose its earnings on August 1, 2024, with an expected EPS of $4.14, reflecting a 6.43% increase from the prior-year quarter [1] - The consensus estimate for revenue is $2.64 billion, indicating a 6.01% increase compared to the same quarter of the previous year [1] - For the entire fiscal year, the Zacks Consensus Estimates project earnings of $17.02 per share and revenue of $10.73 billion, representing changes of +11.75% and +8.69%, respectively, from the prior year [7] Stock Performance - The latest trading session saw Vertex Pharmaceuticals ending at $495.91, marking a +0.88% adjustment from the previous day's close [4] - Over the past month, shares of Vertex Pharmaceuticals gained 4.88%, while the Medical sector gained 0.31% and the S&P 500 gained 0.43% [10] Valuation Metrics - Vertex Pharmaceuticals has a PEG ratio of 2.26, which is comparable to the industry average PEG ratio of 2.27 [6] - The company currently has a Forward P/E ratio of 28.88, representing a premium compared to its industry's average Forward P/E of 24.36 [8] Analyst Ratings - Vertex Pharmaceuticals holds a Zacks Rank of 3 (Hold), with the consensus EPS projection remaining stagnant over the past 30 days [2] - The Medical - Biomedical and Genetics industry, which includes Vertex, has a Zacks Industry Rank of 71, placing it in the top 29% of all industries [12]